Dasatinib as a bone-modifying agent: anabolic and anti-resorptive effects - Wikidata - awgldk - TriplyDB

Dasatinib as a bone-modifying agent: anabolic and anti-resorptive effects

Dasatinib as a bone-modifying agent: anabolic and anti-resorptive effects

http://www.wikidata.org/entity/Q28730433

about

Tyrosine kinase inhibitors and mesenchymal stromal cells: effects on self-renewal, commitment and functions Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers Novel Phenotypic Outcomes Identified for a Public Collection of Approved Drugs from a Publicly Accessible Panel of Assays A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients.The Src family kinase inhibitor dasatinib delays pain-related behaviour and conserves bone in a rat model of cancer-induced bone pain.Dissecting the role of bone marrow stromal cells on bone metastases.Multiple myeloma mesenchymal stromal cells: Contribution to myeloma bone disease and therapeutics Dynamic interplay between bone and multiple myeloma: emerging roles of the osteoblast P2X7 Receptor Function in Bone-Related Cancer.The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects.Systematic screen with kinases inhibitors reveals kinases play distinct roles in growth of osteoprogenitor cells Adverse skeletal effects of drugs - beyond Glucocorticoids.Monitoring Cell-surface N-Glycoproteome Dynamics by Quantitative Proteomics Reveals Mechanistic Insights into Macrophage Differentiation.Molecular mechanisms, current management and next generation therapy in myeloma bone disease.Current trends in bone tissue engineering.Dasatinib inhibits mammary tumour development in a genetically engineered mouse model.Multiparameter Analysis of Off-Target Effects of Dasatinib on Bone Homeostasis in Patients With Newly Diagnosed Chronic Myelogenous Leukemia.Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: implications in myeloma progression and myeloma bone disease.The tyrosine kinase inhibitor GNF-2 suppresses osteoclast formation and activity.NS-018 reduces myeloma cell proliferation and suppresses osteolysis through inhibition of the JAK2 and Src signaling pathways.Therapeutic effects of the novel subtype-selective histone deacetylase inhibitor chidamide on myeloma-associated bone disease

P2860

Q28078946-F81D6714-A9D8-4D21-A9D7-8F88A05A2EFB Q28082793-EC35BF06-0C42-4DE0-9424-7819CF0EF758 Q28546583-D6F0C894-8D06-4184-9EAC-533FF2370B11 Q33415009-078365A1-2DFA-42A1-B878-A053CCD14E9B Q33881060-14551DCA-508C-45BE-BB3F-5E096E36ADA3 Q33904588-7158B967-F0F0-404C-8FCF-D6BB259F7C61 Q34038854-F01F2F29-9211-4A25-B1F4-F7113A2500AC Q36086488-4600B3D0-40B8-489C-80E9-03636872DC9A Q36200053-EE4C27EA-790D-4F41-90FF-9AFF0F676F4C Q37166798-B94AD57A-D077-4CA0-82C9-49C30D2BB59E Q37228831-BA91A6C8-A29B-4BB3-89B5-BC438C5FFF7E Q38231316-FB825096-6BDA-495C-B112-04416902256B Q38710906-6B662F21-A937-4342-9EC2-D22D43F794E7 Q38749233-83045DC7-A79D-46DF-B9F3-BCA24B058969 Q38923797-519339E8-232D-464A-8EBC-C60A28138949 Q39160945-A31A5016-EA5F-46D4-938A-AB1396C7EFFE Q40397359-1B7D84D8-6111-48AB-A827-784E1A8E70F9 Q42158465-78C21CB2-22EE-4907-ABB2-145B877B625D Q44681011-5937C057-2CE7-4576-A2A7-F828E9BF287B Q55292078-D643EED0-4AF5-483C-BF89-23D110B56DA0 Q57172251-71EDF16D-9F41-43FF-89BB-AC21670B678A

P2860

Dasatinib as a bone-modifying agent: anabolic and anti-resorptive effects

http://www.wikidata.org/entity/Q28730433

description

2012 թուականին հրատարակուած գիտական յօդուած

@hyw

2012 թվականին հրատարակված գիտական հոդված

@hy

article publié dans la revue scientifique PLoS ONE

@fr

artículu científicu espublizáu en 2012

@ast

im Januar 2012 veröffentlichter wissenschaftlicher Artikel

@de

scientific article (publication date: 2012)

@en

vedecký článok (publikovaný 2012)

@sk

vědecký článek publikovaný v roce 2012

@cs

wetenschappelijk artikel (gepubliceerd in 2012)

@nl

наукова стаття, опублікована у 2012

@uk

name

Dasatinib as a bone-modifying agent: anabolic and anti-resorptive effects

@ast

Dasatinib as a bone-modifying agent: anabolic and anti-resorptive effects

@en

Dasatinib as a bone-modifying agent: anabolic and anti-resorptive effects

@nl

type

label

Dasatinib as a bone-modifying agent: anabolic and anti-resorptive effects

@ast

Dasatinib as a bone-modifying agent: anabolic and anti-resorptive effects

@en

Dasatinib as a bone-modifying agent: anabolic and anti-resorptive effects

@nl

prefLabel

Dasatinib as a bone-modifying agent: anabolic and anti-resorptive effects

@ast

Dasatinib as a bone-modifying agent: anabolic and anti-resorptive effects

@en

Dasatinib as a bone-modifying agent: anabolic and anti-resorptive effects

@nl

P1433

Q28730433-4BA5EAFC-A9A7-4ECD-85DD-5CC189499460

P1476

Q28730433-7EB9DCD2-F4DF-48B9-B150-BCF21C4FBF3F

P2093

Q28730433-2F069510-9E6A-4CF8-8907-61DD7FC95E4E

Q28730433-646785B1-BADF-4240-B719-9EDFB45F29B3

Q28730433-72069828-B164-44F3-A014-D368F9B2D56F

Q28730433-7D68EDFB-4A49-4F9C-9147-D4A92F498DCB

Q28730433-91EA8CB7-6007-46C2-8341-8871D5957166

Q28730433-9A1D45E5-8B0E-4433-A27B-3307E94290FD

Q28730433-D520BB30-102E-4F66-8423-DEA1F13B66E0

Q28730433-DB66544F-0B01-49BD-A5AD-96EC63C06E52

Q28730433-E911F5A1-4C14-492B-986E-BF35B887EA0D

P2860

Q28730433-0AD16EE1-20CC-41D3-9471-7FFF5F13D631

Q28730433-166F79A2-4EC9-47BE-B071-837A50108ACF

Q28730433-212DCBE2-1ACB-4D37-8101-18920DBE768C

Q28730433-21A20CD1-8355-4FCD-AD3D-ADACC8B1EFBD

Q28730433-257A8262-DA58-4579-BF3F-39149832508E

Q28730433-30C013A1-7FD9-4861-9785-282EBFFF1844

Q28730433-3366F89C-DA1B-4E1E-9367-2A350B814985

Q28730433-35ACA691-48B5-4ADF-B8F5-91246CCDB495

Q28730433-37178A90-3BA3-447E-8584-14A14A420998

Q28730433-3887BF85-CFC5-4858-988E-8E7A294DBACD

P304

Q28730433-27A888CF-1BF2-4F8C-92CF-D56AE632A04C

P31

Q28730433-4776F0D3-0194-41D0-A615-7B637EF5B84B

P356

Q28730433-DC39A684-DE27-4DE3-8ADC-6A9FD8FF3FD1

P407

Q28730433-B90975C6-54FF-4F29-9F75-5736D8111C50

P433

Q28730433-F697A81F-B993-4E7B-8BCC-456438124F59

P478

Q28730433-E8BE0C19-F9AC-423D-B707-DD933D2F1FE8

P50

Q28730433-50BE8675-82A6-4CF7-B9DE-54194FDB061F

Q28730433-59D368E6-C169-4AFB-BDF5-09F45F277950

Q28730433-5C77A4BB-9776-4FBB-AD57-9CF8289BAE3F

Q28730433-859AFE60-C355-4D29-816F-9666811E6FF6

Q28730433-A6CC29A4-84C8-4B65-B0D2-B23E44211B11

P577

Q28730433-9FCAD877-7435-41BE-8EB6-FFCA16C7C6BC

P5875

Q28730433-2CB9AE48-4F4E-44C4-9AD8-EF0C9775F1F9

P698

Q28730433-A3B687F3-4281-4D31-9888-3CE9B1D767D9

P932

Q28730433-2BBE0214-4314-4894-BC0F-9CF2A8B3F1BF

P356

JOURNAL.PONE.0034914

P1433

P1476

Dasatinib as a bone-modifying agent: anabolic and anti-resorptive effects

@en

P2093

Antonio Garcia-Gomez

http://www.w3.org/2001/XMLSchema#string

Atanasio Pandiella

http://www.w3.org/2001/XMLSchema#string

Carlos Santamaria

http://www.w3.org/2001/XMLSchema#string

Edvan Crusoe

http://www.w3.org/2001/XMLSchema#string

Francis Y Lee

http://www.w3.org/2001/XMLSchema#string

Juan F Blanco

http://www.w3.org/2001/XMLSchema#string

Pilar Hernández-Campo

http://www.w3.org/2001/XMLSchema#string

Rosa M Fisac-Herrero

http://www.w3.org/2001/XMLSchema#string

Teresa Hernández-Iglesias

http://www.w3.org/2001/XMLSchema#string

P2860

Gene expression profiling of human mesenchymal stem cells derived from bone marrow during expansion and osteoblast differentiation

Human primary osteoclasts: in vitro generation and applications as pharmacological and clinical assay

Multilineage potential of adult human mesenchymal stem cells

Wnt/beta-catenin signaling in development and disease

Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement

Bone resorption by osteoclasts

A quantitative analysis of kinase inhibitor selectivity

Dasatinib: a new step in molecular target therapy

Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand.

The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblasts

P304

e34914

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0034914

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Fermin Sanchez-Guijo

Mercedes Garayoa

Jesus San Miguel

P577

2012-04-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

224856265

http://www.w3.org/2001/XMLSchema#string

P698

22539950

http://www.w3.org/2001/XMLSchema#string

P932

3335111

http://www.w3.org/2001/XMLSchema#string